BioNTech says lung cancer drug candidate prolonged lives in trial

BioNTech said its late-stage trial showed gotistobart delivered a clinically meaningful overall-survival benefit versus standard treatment in a specified form of lung cancer. The positive pivotal-trial result strengthens the drug candidate's clinical and potential commercial outlook, with likely implications for BioNTech shares and oncology peers.